[go: up one dir, main page]

MX2011009339A - Nueva forma cristalina iv de la agomelatina, preparacion y uso de la misma. - Google Patents

Nueva forma cristalina iv de la agomelatina, preparacion y uso de la misma.

Info

Publication number
MX2011009339A
MX2011009339A MX2011009339A MX2011009339A MX2011009339A MX 2011009339 A MX2011009339 A MX 2011009339A MX 2011009339 A MX2011009339 A MX 2011009339A MX 2011009339 A MX2011009339 A MX 2011009339A MX 2011009339 A MX2011009339 A MX 2011009339A
Authority
MX
Mexico
Prior art keywords
crystalline form
agomelatine
preparation
application
new crystalline
Prior art date
Application number
MX2011009339A
Other languages
English (en)
Inventor
Peng Zhang
Hanbin Shan
Zhedong Yuan
Xudong Jiang
Yu Huang
Hubo Wang
Xufeng Cao
Xingdong Cheng
Xiong Yu
Original Assignee
Servier Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41370233&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2011009339(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Servier Lab filed Critical Servier Lab
Publication of MX2011009339A publication Critical patent/MX2011009339A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C231/00—Preparation of carboxylic acid amides
    • C07C231/22—Separation; Purification; Stabilisation; Use of additives
    • C07C231/24—Separation; Purification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/16—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C07C233/17—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C07C233/18—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Anesthesiology (AREA)
  • Endocrinology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Battery Electrode And Active Subsutance (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La invención proporciona una nueva forma cristalina de la agomelatina, la preparación y uso de ésta. El diagrama de difracción de rayos X en polvo de la forma cristalina de la agomelatina muestra picos principales en los ángulos de difracción 2? 11.13°, 11.82°, 17.49°, 18.29°, 19.48°, 19.72°, 20.50°, 21.76°, 22.54°, 22.97°, 24.56°, 25.36°, 27.16° y 31.93°. Dicha nueva forma cristalina se caracteriza por una alta pureza, estabilidad y buena reproducibilidad, y es así ventajosa para la formulación farmacéutica. Además, la estabilidad y solubilidad de dicha forma cristalina también son superiores a las distintas formas cristalinas existentes.
MX2011009339A 2009-03-10 2010-03-09 Nueva forma cristalina iv de la agomelatina, preparacion y uso de la misma. MX2011009339A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN200910047329.2A CN101585779B (zh) 2009-03-10 2009-03-10 阿戈美拉汀的晶型vi及其制备方法和应用
PCT/CN2010/070931 WO2010102554A1 (zh) 2009-03-10 2010-03-09 阿戈美拉汀的新晶型ⅵ及其制备方法和应用

Publications (1)

Publication Number Publication Date
MX2011009339A true MX2011009339A (es) 2011-09-27

Family

ID=41370233

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2011009339A MX2011009339A (es) 2009-03-10 2010-03-09 Nueva forma cristalina iv de la agomelatina, preparacion y uso de la misma.

Country Status (27)

Country Link
US (1) US8614251B2 (es)
EP (1) EP2431355A4 (es)
JP (1) JP2012519715A (es)
KR (1) KR20110123266A (es)
CN (1) CN101585779B (es)
AP (1) AP3049A (es)
AU (1) AU2010223720B2 (es)
BR (1) BRPI1013249A2 (es)
CA (1) CA2754276A1 (es)
CL (1) CL2011002231A1 (es)
CO (1) CO6410293A2 (es)
CR (1) CR20110457A (es)
CU (1) CU20110162A7 (es)
EA (1) EA019127B1 (es)
EC (1) ECSP11011309A (es)
GE (1) GEP20146114B (es)
HN (1) HN2011002408A (es)
IL (1) IL214683A0 (es)
MA (1) MA33100B1 (es)
MX (1) MX2011009339A (es)
NI (1) NI201100167A (es)
PE (1) PE20120653A1 (es)
SG (2) SG177886A1 (es)
TN (1) TN2011000426A1 (es)
UA (1) UA100476C2 (es)
WO (1) WO2010102554A1 (es)
ZA (1) ZA201106049B (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101585779B (zh) * 2009-03-10 2014-04-02 上海医药工业研究院 阿戈美拉汀的晶型vi及其制备方法和应用
WO2011006387A1 (zh) * 2009-07-11 2011-01-20 浙江华海药业股份有限公司 阿戈美拉汀的制备方法、阿戈美拉汀晶形及其制备方法
CN101955440B (zh) * 2009-07-17 2014-04-09 江苏万特制药有限公司 一种阿戈美拉汀新晶型及其制备方法
CN102050756A (zh) * 2009-11-09 2011-05-11 北京利乐生制药科技有限公司 阿戈美拉汀新晶型及其制备方法
CN102190595A (zh) 2010-03-17 2011-09-21 上海医药工业研究院 阿戈美拉汀溴化氢水合物及其制备方法
CN102557979B (zh) * 2010-12-16 2014-11-26 北大方正集团有限公司 一种阿戈美拉汀的晶型、其制备方法、用途及药物组合物
WO2012093402A1 (en) * 2011-01-04 2012-07-12 Symed Labs Limited Processes for the preparation of n-[2-(7-methoxy-1-naphthyl)ethyl]acetamide
CN102690209A (zh) * 2011-03-23 2012-09-26 上海医药工业研究院 阿戈美拉汀的混晶(形式-ⅷ)、其制备方法、应用和包含其的药物组合物
CN102690210A (zh) * 2011-03-23 2012-09-26 上海医药工业研究院 阿戈美拉汀的新晶型ⅶ、其制备方法、应用和包含其的药物组合物
FR2978916B1 (fr) 2011-08-10 2013-07-26 Servier Lab Composition pharmaceutique solide pour administration buccale d'agomelatine
WO2013082302A1 (en) 2011-11-30 2013-06-06 Ratiopharm Gmbh Agomelatine-urea complex and crystalline forms thereof
FR3001894A1 (fr) 2013-02-08 2014-08-15 Servier Lab Composition pharmaceutique solide pour administration buccale d'agomelatine
CN103690499B (zh) * 2013-12-23 2015-05-06 天津泰普药品科技发展有限公司 一种稳定的晶i型阿戈美拉汀片剂及其制备方法
WO2015124496A1 (en) 2014-02-19 2015-08-27 Synthon B.V. Pharmaceutical composition comprising amorphous agomelatine
EP3075724B1 (en) 2015-03-31 2023-07-12 F.I.S.- Fabbrica Italiana Sintetici S.p.A. Solid form of agomelatine

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2658818B1 (fr) * 1990-02-27 1993-12-31 Adir Cie Nouveaux derives a structure naphtalenique, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
FR2866334B1 (fr) * 2004-02-13 2006-05-26 Servier Lab Nouveau procede de synthese du (7-methoxy-1-naphtyl) acetonitrile et application a la synthese de l'agomelatine
FR2866335B1 (fr) * 2004-02-13 2006-05-26 Servier Lab Nouveau procede de synthese de l'agomelatine
FR2889523B1 (fr) * 2005-08-03 2007-12-28 Servier Lab Nouvelle forme cristalline v de l'agomelatine, son procede de preparation et les compositions pharmaceutiques qui la contiennent
FR2889522B1 (fr) * 2005-08-03 2007-12-28 Servier Lab Nouvelle forme cristalline iv de l'agomelatine, son procede de preparation et les compositions pharmaceutiques qui la contiennent
FR2889521B1 (fr) * 2005-08-03 2007-12-28 Servier Lab Nouvelle forme cristalline iii de l'agomelatine, son procede de preparation et les compositions pharmaceutiques qui la contiennent
FR2899472B1 (fr) * 2006-04-07 2008-09-12 Servier Lab Utilisation de l'agomelatine pour l'obtention de medicaments destines au traitement du trouble anxiete generalisee
FR2923482B1 (fr) * 2007-11-09 2010-01-29 Servier Lab Nouvelle forme cristalline vi de l'agomelatine, son procede de preparation et les compositions pharmaceutiques qui la contiennent
CN101585779B (zh) * 2009-03-10 2014-04-02 上海医药工业研究院 阿戈美拉汀的晶型vi及其制备方法和应用
EP2319827A1 (en) * 2009-11-09 2011-05-11 Ratiopharm GmbH Process for the production of polymorph form I of agomelatine

Also Published As

Publication number Publication date
US20120004313A1 (en) 2012-01-05
NI201100167A (es) 2012-01-11
IL214683A0 (en) 2011-11-30
WO2010102554A1 (zh) 2010-09-16
ZA201106049B (en) 2012-10-31
CN101585779B (zh) 2014-04-02
US8614251B2 (en) 2013-12-24
MA33100B1 (fr) 2012-03-01
JP2012519715A (ja) 2012-08-30
GEP20146114B (en) 2014-07-10
CR20110457A (es) 2011-09-21
CO6410293A2 (es) 2012-03-30
ECSP11011309A (es) 2011-10-31
SG173692A1 (en) 2011-09-29
KR20110123266A (ko) 2011-11-14
TN2011000426A1 (en) 2013-03-27
AU2010223720A1 (en) 2011-09-08
CL2011002231A1 (es) 2012-02-03
CU20110162A7 (es) 2012-02-15
EA201101304A1 (ru) 2012-04-30
UA100476C2 (en) 2012-12-25
SG177886A1 (en) 2012-02-28
EA019127B1 (ru) 2014-01-30
HN2011002408A (es) 2014-06-23
PE20120653A1 (es) 2012-06-14
EP2431355A1 (en) 2012-03-21
EP2431355A4 (en) 2012-08-08
AP3049A (en) 2014-11-30
AP2011005914A0 (en) 2011-10-31
CA2754276A1 (en) 2010-09-16
AU2010223720B2 (en) 2012-05-03
BRPI1013249A2 (pt) 2016-04-05
CN101585779A (zh) 2009-11-25

Similar Documents

Publication Publication Date Title
TN2011000426A1 (en) New crystalline form vi of agomelatine, preparation method and application thereof
IL219719A0 (en) Method for producing fine powder and the fine powder and the fine powder produced by hte same
PL2058296T3 (pl) Nowa postać krystaliczna VI agomelatyny, sposób jej wytwarzania i kompozycje farmaceutyczne ją zawierające
PH12013502009A1 (en) Strip of cu-co-si-based copper alloy for electronic materials and the method for producing the same
WO2011056511A3 (en) 4,6-diaminopyrimidine stimulators of soluble guanylate cyclase
GEP20094577B (en) New crystalline form iv of agomelatine, a process for its preparation and pharmaceutical compositions containing it
TN2012000435A1 (en) Agomelatine hydrochloride hydrate and preparation thereof
PL2513918T3 (pl) Kompozycja proszku ferromagnetycznego i sposób jej produkcji
UA83719C2 (ru) Кристаллическая форма iii агомелатина, способ ее получения и фармацевтическая композиция, которая ее содержит
IL219959A (en) 7 - [5,3-Hydroxy-2- (3-Hydroxy-5-Phenyl-Pent-1-Inyl) -Cyclopnital] - n-Ethyl-Hept-5-Inamide (Bimetoprost) in crystalline form II and its pharmaceutical preparations
PH12015502122A1 (en) Sovaprevir polymorphs and methods of manufacturing thereof
ZA200810509B (en) Process for the preparation of pure dimethyl ether
WO2008081041A3 (en) Amorphous and crystalline forms of rivastigmine hydrogentartrate
EP2155609A4 (en) STEAM PHASE REACTION FLUORINATED MAGNESIUM OXIDE POWDER AND METHOD FOR PREPARING THE SAME
WO2012025941A3 (en) Processes for the preparation of fesoterodine
IL226194A (en) A Method for Preparing a History of 2,2-Diplooroethylamine Beginning with n- (2,2- Diplooroethyl) Prof-2-An-1-Amine
GB201114785D0 (en) 2-Fluoro-1,3-benzodithiol 1,1,3,3-tetraoxide derivatives, process for the preparation of sam, and process for the preparation of monofluoromethyl-coating
TW200640854A (en) Methods of making pravastatin sodium
PL392169A1 (pl) Nowe propioniany 2-(4,4-dimetylocykloheks-2-en-1-ylo)etylu i sposób ich otrzymywania
PL392176A1 (pl) Nowe propioniany 2-(5,5-dimetylocykloheks-2-en-1-ylo)etylu i sposób ich otrzymywania
WO2009002510A3 (en) Crystalline polymorph of exemestane
BR112012014762A2 (pt) forma polimorfa de nevirapina e sua preparação
PL392173A1 (pl) Nowy octan R-(-)-2-(5,5-dimetylocykloheks-2-en-1-ylo)etylu i sposób jego otrzymywania
PL392172A1 (pl) Nowe aldehydy (4,4-dimetylocykloheks-2-en-1-ylo)octowe i sposób ich otrzymywania
PL392174A1 (pl) Nowe octany 2-(5,5-dimetylocykloheks-2-en-1-ylo)etylu i sposób ich otrzymywania

Legal Events

Date Code Title Description
HH Correction or change in general
FA Abandonment or withdrawal